AFLIBERCEPT “EYLEA®” FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE ROUTINE CLINICAL PRACTICE


Cite item

Full Text

Abstract

Objective: to evaluate the anatomical and functional characteristics of “Eylea®” treatment in patients with «wet» agerelated macular degeneration in real clinical practice. Materials and methods. We was performed a retrospective analysis of the results of treatment of 6 eyes (6 patients) with “wet” age-related macular degeneration. The mean age was 81.8 years (79-88), evaluation criteria were the best corrected visual acuity, central thickness of the retina (central subfield thickness) and the height of the pigment epithelium detachment. Results of the study. After 6 injections, best corrected visual acuity (0.44 ± 0.17) increased and had a statistically significant difference relative to baseline (p = 0.042, p < 0.05). Central subfield thickness after 6 injections decreased to 243.4 ± 33.1 (p = 0.043, p < 0.05). Pigment epithelium detachment after 6 injections (170.4 ± 120.8 microcres) remained stable (p = 0.095, p > 0.05). Conclusion. Improvement and stabilization of anatomical and functional characteristics in the treatment with “Eylea®” in patients with a “wet” form of age-related macular degeneration with the correct dosing regimen allows real clinical practice to be brought closer to indicators that meet world standards in the treatment of this disease (4 figs, bibliography: 9 refs).

About the authors

V S Khudaynazarova

Ophthalmological center “Vision”

Saint Petersburg, Russia

G M Arslanov

Kazan (Volga region) Federal University

Kazan, Russia

N Yu Dal’

Ophthalmological center “Vision”

Saint Petersburg, Russia

M I Krasavina

Ophthalmological center “Vision”

Saint Petersburg, Russia

E S Onishchenko

Ophthalmological center “Vision”

Saint Petersburg, Russia

A N Panfilova

Ophthalmological center “Vision”

Saint Petersburg, Russia

N V Chistyakova

Ophthalmological center “Vision”

Saint Petersburg, Russia

References

  1. Либман Е. С. Инвалидность вследствие патологии органа зрения. В кн.: Аветисов С. Е., Егоров Е. А., Мошетова Л. К., Нероев В. В., Тахчиди Х. П. Офтальмология. Национальное руководство. М.: ГЭОТАР-Медиа; 2008: 19-26.
  2. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009; 20 (4): 158-63.
  3. Бойко Э. В., Сосновский С. В., Березин Р. Д., Коскин С. А., Ян А. В., Куликов А. Н., Мальцев Д. А., Бутикова О. В., Давыдова В. В., Жукова К. Е.) Антиангиогенная терапия в офтальмологии. СПб.: ВМедА имени С. М. Кирова; 2013).
  4. Heier J. S. , Brown D. M., Chong V., Korobelnik J. F., Kaiser P. K., Nguyen Q. D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G. D., Stahl N., Vitti R., Berliner A. J., Soo Y., Anderesi M., Groetzbach G., Sommerauer B., Sandbrink R., Simader C., Schmidt-Erfurth U. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012; 119: 2537-48.
  5. Thulliez M., Angoulvant D., Pisella P., Bejan-Angoulvant T. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated with Intravitreal Anti- Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmol. 2018. Available at: https://jamanetwork.com/ journals/jamaophthalmology/article-abstract/2676023 (accessed 03.07.2018).
  6. Talks J. S., Lotery A. J., Ghanchi F., Sivaprasad S., Johnston R. L., Patel N., McKibbin M., Bailey C., Mahmood S. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology. 2016; 123 (2): 337-43.
  7. Lotery A., Griner R., Ferreira A., Milnes F., Dugel P. Real-World Visual Acuity Outcomes between Ranibizumab and Aflibercept in Treatment of Neovascular AMD in a Large US Data Set. Eye. 2017; 1697-706.
  8. Бойко Э. В., Сосновский С. В., Березин Р. Д., Качерович П. А., Тавтилова Д. А. Интравитреальные инъекции: теория и практика. Офтальмологические ведомости. 2010; 3 (2): 28-35.
  9. Ashraf M., Souka A. R. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond). 2017; 31 (11): 1523-36.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Khudaynazarova V.S., Arslanov G.M., Dal’ N.Y., Krasavina M.I., Onishchenko E.S., Panfilova A.N., Chistyakova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).